Compare FuelCell Energy Inc (FCEL) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FuelCell Energy Inc vs Gilead Sciences, Inc. — how do they compare? FuelCell Energy Inc trades at $17.17 (market cap $1.62B), while Gilead Sciences, Inc. trades at $135.64 (market cap $163.51B). The key difference: Gilead Sciences, Inc. is far larger — about 100.9× FuelCell Energy Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while FuelCell Energy Inc pays none. Which is the better fit depends on your goals.
| FCEL | GILD | |
|---|---|---|
Market Cap | $1.62B | $163.51B |
Sector | Industrials | Health |
52-Week High | $36.01 | $155.80 |
52-Week Low | $3.92 | $108.22 |
Enterprise Value | $1.47B | $178.05B |
Dividend Yield | — | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FuelCell Energy (FCEL) trades at $17.35, down 18.74% over 24 hours, reflecting recent volatility. The stock shows a bearish technical signal with support at $17 and resistance at $21. Fundamentally, the company reported a net loss of $187.90 million on $158.16 million revenue in 2025, with negative profit margins persisting. Recent news highlights a partnership with Siemens for scalable fuel cell solutions and a $225 million stock offering that caused dilution concerns. Analyst consensus is mixed with a $20.75 price target.
FCEL presents high-risk growth potential driven by AI data center energy demand and strategic partnerships, but faces significant challenges including consistent losses, cash burn, and shareholder dilution. The stock's outlook hinges on execution of commercial projects and path to profitability, with substantial downside risk if growth catalysts fail to materialize.
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
